Skip to content
MARKETS / BALCAO / INIS
BALCAO · INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, AND CONTROL · SMALL CAP

Radnostix Inc. INIS

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$13.1M
▼ 6.0% YoY
$-908,002
▼ 10690.2% YoY
$86,008
In brief

What this company does

Radnostix Inc. (the “Company”, “we”, “us” and “our”) manufactures a wide range of radioisotope-focused products used in variety of medical and industrial applications. On December 23, 2025, we filed a Certificate of Amendment in the state of Texas for the sole purpose of amending our Certificate of Formation to change our corporate name from International Isotopes Inc. to Radnostix, Inc. Our core business consists of five reportable segments which include: Theranostics Products, Cobalt Products, Calibration & Reference Products (previously called Nuclear Medicine Standards), Medical Devices, and Fluorine Products. To our knowledge, our FDA approved generic sodium iodide I-131 drug product is the only generic product of this type manufactured in the U.S. and offers customers an attractive domestic alternative to the single existing foreign commercial drug manufacturer. We started the Medical Devices segment in 2024 and many of our products in this segment remain under development. We established the fluorine products business segment in 2004 to support production and sale of various fluoride gases produced using our Fluorine Extraction Process ("FEP").

Written from the business description in Radnostix Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth
USD 13.1M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 13.1 · Net income -0.9
5M10M-2M201020122014201620182020202220242025
Compound annual growth
+5.3%
+6.9%
+6.3%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +6.9% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−7 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -7.3% · Net -6.9%
10%20%-20%-40%201020122014201620182020202220242025
ROE
FY2025 · ROE -22.6%
-500%-1000%-1500%201020122014201620182020202220242025

Each USD of equity lost 23 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 0.1
0.4M0.8M-0.8M-1.6M201020122014201620182020202220242025

Total assetsUSD 17.8M
EquityUSD 3.7M
CashUSD 1.7M
Gross debtUSD 2.1M
Net debtUSD 399,253.00
Current ratio1.16×

Net debt stands at 11% of equity.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.0····
Operating income $B−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0·
Income tax $B0.00.00.00.00.00.00.00.00.00.00.00.0−0.0−0.0−0.0·
Net income $B−0.00.0−0.00.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B0.0−0.00.0−0.0−0.00.0−0.00.0−0.0−0.00.00.0····
EPS, diluted $0.000.000.000.000.000.01·0.00−0.010.000.000.00−0.01−0.01−0.02−0.02
Dividend / sh $················
Payout %················
ROE %−22.60.2−20.78.6−54.6···−1579.8−72.0−49.0−35.6−45.8−33.8−99.6−146.3
Shares out B0.530.520.520.510.500.420.420.410.410.400.400.370.370.360.360.32

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 63 reconciliationsAUDITED

Reconciled in 16 of 19 fiscal years. 32 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityIndustrial Instruments For Measurement, Display, and Control
Listed onOTC market
Incorporated inTexas
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image